MedTrace Logo

Phase 2 Study of CU104 in Moderate-Severe Ulcerative Colitis

NCT05907330 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2023-06-18

No results posted yet for this study

Summary

The study is designed to investigate efficacy and safety of CU104 in patients with moderate to severe ulcerative colitis.

Conditions

Interventions

DRUG

CU104

CU104 will administer the study drug once a day after a meal

DRUG

Placebo

Placebo will administer the study drug once a day after a meal

Sponsors & Collaborators

  • Curacle Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-01
Primary Completion
2026-02-28
Completion
2026-03-31
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05907330 on ClinicalTrials.gov